Navigation Links
BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
Date:7/17/2008

us (grade 3 and 4) treatment related adverse events. A substantial reduction in chemotherapy-induced renal (kidney) toxicity and nausea/vomiting was also observed in the Tavocept group.

"The observations from the U.S. Tavocept Trial are extremely encouraging," said Frederick H. Hausheer, M.D., chairman & chief executive officer of BioNumerik. "The increase in patient survival with Tavocept compares favorably to observations seen for other cancer drugs. For example, the cancer drug Avastin(R) (also known as bevacizumab) was approved in the United States to treat lung cancer while exhibiting a survival increase of approximately two months when used with a standard chemotherapy treatment regimen. Recent data for the cancer drug Erbitux(R) (also known as cetuximab) demonstrated a survival increase of about 1.2 months compared to chemotherapy alone in patients with advanced epidermal growth-factor receptor (EGFR)- detectable non-small-cell lung cancer."

Earlier this year, BioNumerik and ASKA Pharmaceutical Co., Ltd. ("ASKA") reported results from a randomized, multi-center Phase III clinical trial of Tavocept that also indicated a survival increase in adenocarcinoma and non- small cell lung cancer patients. That clinical trial (the "Japan Tavocept Trial") was conducted in Japan by ASKA and involved 182 advanced non-small cell lung cancer patients who received the chemotherapy drugs paclitaxel and cisplatin every three weeks. Half of the patients in the trial received Tavocept along with their chemotherapy, while the other half received a placebo and chemotherapy. The results from the Japan Tavocept Trial demonstrated an observed increase in median survival time of approximately 138 days (4.5 months) for adenocarcinoma patients receiving Tavocept as compared to those receiving placebo. For all non-small cell lung cancer patients participating in the Japan Tavocept Trial, the median survival time observed for patients receiving Tavocept was approximately 40 d
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
2. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
8. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
9. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
10. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Sept. 4, 2015  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... at the Wells Fargo Securities 2015 Healthcare Conference in ... September 10 th at 2:30 p.m. Eastern Time. To ... discussion, please visit the Investors section of the Company,s Web ... for 14 days after the event.  Orexigen Contact: ...
(Date:9/4/2015)... , Sept. 4, 2015  Allergan plc (NYSE: ... Brent Saunders , CEO and President of Allergan, will ... the Morgan Stanley Global Healthcare Conference 2015 in ... http://photos.prnewswire.com/prnh/20150612/222796LOGO The presentation will take place ... at the Grand Hyatt New York, 109 East 42nd Street, ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gvzjt8/investigation ) has announced ... Ibandronate Market, 2010-2019" report to their offering. ... name of Bondronat in Germany and ... approved by the FDA to come into the market as ... Boniva. However, since drug makers later developed more convenient dose, ...
Breaking Medicine Technology:Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Investigation Report on China's Sodium Ibandronate Market 2010-2019 2
(Date:9/4/2015)... ... ... The Schmidt National Law Group filed an Essure® lawsuit against Bayer and ... Group, a leading firm in mass-tort litigation, has filed a lawsuit in the federal ... other Bayer affiliates for injuries alleged to have been caused by her Essure® contraceptive ...
(Date:9/4/2015)... ... September 04, 2015 , ... Georgia ... is launching a charity effort to provide for the family of Grace, a ... enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability to ...
(Date:9/4/2015)... Monroe, NC (PRWEB) , ... September 04, 2015 ... ... Girl’s Night out to benefit Core Compassion Project. Core Compassion Project is ... a specialized program to reduce the side effects of cancer treatments and recover ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... that CEREC technology is now available at CitiDent. CEREC is a newer method ... addition to saving time for patients by eliminating the need for multiple appointments, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: ... provider of pharmacy benefits management technology and services, ... maintenance and professional services agreements, and a software ... The agreements provide Prime with software licensing, software ...
... Chia Seed Flour is the buzz when it comes to ... Seed Flour is made from the tiny chia seeds. The ... It is the most nutritious grain available today. Now, thanks ... Flour is once again available for dinner tables everywhere. It ...
... Industry-leading and renowned laparoscopic bariatric surgeon Dr. ... selected by medical device manufacturers to introduce a ... County Region.Dr. Smith continues to lead the way ... as SILS (Single Incision Laparoscopic Surgery), at Specialty ...
... SAO PAULO and PHILADELPHIA, May 20 moksha8, Inc. ... with Roche to commercialize an additional portfolio of products ... , , moksha8 will commercialize products in ... The product portfolio consists of well-known brands including Rivotril(R), ...
... Area high schoolers take to the stage at the House of ... most creative seat belt messagesCLEVELAND, May 20 Local teens had ... -- at the House of Blues at noon on Tuesday, May ... Lose It High School Seat Belt Challenge, sponsored by Kohl,s, ...
... May 20 A three-minute video gave Midwesterners all the ... when Kansas City Public Television aired "Imagine KC." The video ... for the benefit of all. The project is the latest ... KC-based studio which has successfully marketed over $6 Billion in ...
Cached Medicine News:Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 2Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 3Health News:SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC 4Health News:Nuchia Foods' Gluten-Free Chia Seed Flour Is a Tasty, Low-Fat Alternative Flour 2Health News:Nuchia Foods' Gluten-Free Chia Seed Flour Is a Tasty, Low-Fat Alternative Flour 3Health News:Dr. Adam Smith Chosen to Help Introduce No-Scar Surgical Weight-Loss Innovations 2Health News:moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 3Health News:Arnold Imaging Video Generates Public Enthusiasm for Light Rail 2
... VERSASTEP™ Plus Short Instrument ... , ,The VERSASTEP™ Plus ... Working Length is a unique ... applications in laparoscopic procedures. It ...
... Trocar consists of a blunt obturator connected ... assembly. , ,The valve body assembly ... to prevent gas leakage when instruments are ... Trocar includes built-in converters to allow insertion ...
... Premium One-Step™ single-use system device is comprised ... device components for creating each access port ... , Step™ insufflation and access needle, ... separately. , Step™ radially expandable sleeve, 100 ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
Medicine Products: